Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Fuji
Boehringer Ingelheim
Cipla
Merck
Express Scripts
Queensland Health
McKinsey
Farmers Insurance

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022332

« Back to Dashboard

NDA 022332 describes ADCIRCA, which is a drug marketed by Eli Lilly Co and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ADCIRCA profile page.

The generic ingredient in ADCIRCA is tadalafil. There are twenty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for 022332
Tradename:ADCIRCA
Applicant:Eli Lilly Co
Ingredient:tadalafil
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 022332
Medical Subject Heading (MeSH) Categories for 022332
Suppliers and Packaging for NDA: 022332
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADCIRCA tadalafil TABLET;ORAL 022332 NDA Aphena Pharma Solutions - Tennessee, LLC 43353-070 N 43353-070-12
ADCIRCA tadalafil TABLET;ORAL 022332 NDA United Therapeutics Corporation 66302-467 N 66302-467-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:May 22, 2009TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:May 21, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:May 19, 2021Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Oct 26, 2020Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Citi
Chinese Patent Office
Cantor Fitzgerald
Baxter
AstraZeneca
Boehringer Ingelheim
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.